Medical Device Adverse Event Monitoring and Re-Evaluation: Reporting and System Building

1. Key takeaways

Adverse event monitoring and re-evaluation is one of the five statutory duties that Article 20, paragraph 1 of the Medical Device Supervision and Administration Regulation (State Council Order No. 739) places on the holder; it is item (3), and it is mandatory.

• Post-market monitoring and serious adverse event reporting during a trial are two regimes, with different legal bases, responsible parties and exits. Confusing them is the most frequent error in system documents.
• A monitoring system needs four layers to run: data collection, signal identification, risk assessment, and reporting and handling. Miss one and effective operation cannot be demonstrated.
• Re-evaluation is not triggered only by a serious incident. Accumulating cases, new literature evidence, overseas regulatory action and signals from similar products all serve.
• Conclusions lead to four exits: change registration (Article 21), filing within 30 days (Article 79 of the Measures), recall (Article 20, paragraph 1, item (4)), and revision of instructions or label.
• An overseas holder lands the chain through its China agent: Article 20, paragraph 2 and Article 14, paragraph 2 of the Measures form the basis of that assistance duty.
• Complaints are a primary signal source. Collecting only spontaneous reports from medical institutions misses much early signal from real-world use.

2. Legal basis

Administrative regulation. Medical Device Supervision and Administration Regulation (State Council Order No. 739), promulgated 9 February 2021, effective 1 June 2021.

• Article 5: risk management, whole-process control, scientific supervision, social co-governance. Article 13: Class I filed, Class II and III registered, with lifecycle liability.
• Article 20, paragraph 1: five duties, item (3) being monitoring and re-evaluation; paragraph 2: the designated Chinese legal entity assists in these duties.
• Article 21: substantive change requires change registration. Article 22, paragraph 1: validity five years, renewal six months before expiry. Article 34: manufacture in-house or by entrustment.

Departmental rules. Measures for the Administration of Medical Device Registration and Filing (SAMR Order No. 47), promulgated 26 August 2021, effective 1 October 2021.

• Article 14, paragraph 2: the overseas applicant or filer designates a Chinese legal entity as agent, to assist in the Article 20 duties and in giving effect to liability. Articles 15, 24: quality system, risk management.
• Articles 42 and 43: serious adverse event reporting during trials, and suspension or termination of a trial.
• Article 79: substantive change requires change registration; other changes filed within 30 days; certificate matters fall within change registration, holder and agent names and addresses within filing. Article 107: fine of RMB 10,000 to 30,000 for failure to file.

Normative and technical documents. Good Clinical Practice (Announcement No. 28 of 2022), 24 March 2022, effective 1 May 2022: nine chapters, 66 articles; Article 3 adopts the Helsinki Declaration ethics, Article 7 requires a sponsor quality system covering the whole trial. Registration Quality Management System Inspection Guideline (Notice No. 50 of 2022), 29 September 2022, effective on issue, repealing Notice No. 19 of 2020.

Practical estimate. No verified provision covers the day counts for individual case reports, the differentiated limits for serious injury and death, or the cycle for periodic risk evaluation reports. Enterprises should follow the rules in force in the national adverse event monitoring information system and the provincial body, and write them into system documents; time limits here are practical estimate only, with no inferred day counts.

3. Expert insights

Post-market monitoring and trial reporting are two regimes. The commonest error in system documents is carrying trial requirements into the post-market phase, or the reverse.

A post-market case handled under suspension logic misclassifies a signal that should open a re-evaluation, while a trial event sent through the post-market route loses the immediate judgement on suspension. GRZAN therefore requires each procedure to state its own basis in its scope clause, with no cross-reference.

Four layers, and one missing layer stops the system. Inspection questions concentrate on the middle layers: a full ledger without thresholds has no identification capability, and an assessment without an exit produces no consequence.

The four must form a one-way flow from collection to identification to assessment to handling; if one breaks, the system is treated as not effectively operating.

Four trigger sources, not only a serious incident.

The third matters most for imports, since action in the country of origin usually predates a domestic signal. Without an overseas tracking mechanism at the agent, exposure has widened by the time domestic cases accumulate, which is why GRZAN lists a weekly overseas regulatory digest as a standing deliverable.

Four exits, and the order of determination decides the consequence.

Determination starts from whether the product is defective, not from which procedure is quicker. The fourth exit is the most overlooked: if risk-benefit no longer holds, the problem surfaces at renewal, when the remedial window has closed.

The domestic chain, with the agent as critical node. Article 20, paragraph 2 and Article 14, paragraph 2 place the landing on the China agent, and each link needs an owner.

The weak point is translation and time difference: assessment at headquarters takes a number of working days (practical estimate), and without an internal deadline in the agreement, domestic submission drifts. Writing response times into the agreement works better than allocating blame afterwards.

4. Practical recommendations

• Separate the scope of the two procedures, each citing its own basis, with no cross-reference.
• Set numerical thresholds for signal identification by failure mode, with trigger count and observation window in the system documents.
• Track overseas regulatory action weekly across origin country and major markets, with a named owner.
• Pre-set an exit for every conclusion, with criteria and responsible post, so no assessment ends without an owner.
• Fix response times in the agent agreement for receipt, translation, submission and follow-up, using receipts as evidence.
• Bring complaints into the vigilance ledger rather than closing them inside customer service.
• Consolidate conclusions twelve months before renewal, since the certificate runs five years with a six-month deadline (practical estimate).

5. Verification checklist

• □ Item (3) of the five duties assigned to a named post
• □ Trial and post-market procedures each state their own basis
• □ Monitoring system has all four layers
• □ Signal thresholds set by failure mode and written into system documents
• □ Complaint records numbered in the vigilance ledger
• □ Re-evaluation procedure covers all four trigger sources
• □ Conclusions mapped to four exits with criteria stated
• □ Filing-scope changes completed within 30 days (Article 79)
• □ Agent agreement sets response times for each link
• □ Imported products have a tracking list of origin-country and other market actions
• □ Receipts and follow-up records retained for every report

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Chinese market. Our team manages adverse event monitoring and recall filings with NMPA, maintains UDI compliance, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com